Insider Transactions in Q2 2024 at Eye Point Pharmaceuticals, Inc. (EYPT)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 23
2024
|
Anthony P Adamis |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+33.33%
|
-
|
|
Jun 03
2024
|
David R Guyer |
SELL
Open market or private sale
|
Direct |
11,625
-75.86%
|
$116,250
$10.3 P/Share
|
|
Jun 03
2024
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,775
+26.29%
|
$29,325
$3.38 P/Share
|
|
May 25
2024
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,627
-7.1%
|
$39,897
$11.16 P/Share
|
|
May 25
2024
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+12.8%
|
-
|
|
May 14
2024
|
David R Guyer |
SELL
Open market or private sale
|
Direct |
11,625
-67.69%
|
$139,500
$12.65 P/Share
|
|
May 14
2024
|
David R Guyer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,775
+23.91%
|
$29,325
$3.38 P/Share
|
|
May 06
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
850,000
+4.88%
|
$10,200,000
$12.03 P/Share
|
|
Apr 18
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
581,765
+3.79%
|
$10,471,770
$18.26 P/Share
|